SCHEMBL31419367

SCHEMBL31419367

O=C(O)c1ncccc1-c1nn[nH]n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
KDM4E B2RXH2 4/20 0.50
AGTR1 P30556 6/20 0.47
AGTR2 P50052 6/20 0.47
PBRM1 Q86U86 1/20 0.46
IDO1 P14902 1/20 0.46
GAA P10253 1/20 0.46
LDHA P00338 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
BLM P54132 1/20 0.46
AGER Q15109 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGDS O60760 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3390642 0.79 KDM4E (0.59) ALDH1A1L3MBTL1MEN1KMT2AKDM4E
SCHEMBL7019052 0.76 ALDH1A1 (0.63) ALDH1A1L3MBTL1MEN1KMT2AAGTR1
SCHEMBL9693400 0.73 KDM4E (0.52) ALDH1A1L3MBTL1MEN1KMT2AKDM4E
SCHEMBL1734017 0.73 IDO1 (0.61) ALDH1A1L3MBTL1MEN1KMT2AKDM4E
SCHEMBL842381 0.72 KDM4E (0.46) ALDH1A1L3MBTL1KMT2AKDM4EGAA
SCHEMBL7350821 0.72 MEN1 (0.62) ALDH1A1L3MBTL1MEN1KMT2AAGTR1
SCHEMBL31419368 0.71 ALDH1A1 (0.51) ALDH1A1L3MBTL1MEN1KMT2AKDM4E
SCHEMBL287699 0.71 KDM4E (0.57) ALDH1A1L3MBTL1KDM4EAGTR1AGTR2
SCHEMBL27940918 0.70 KDM4E (0.52) ALDH1A1L3MBTL1KDM4ECYP3A4MAPT
SCHEMBL3589515 0.70 MEN1 (0.55) ALDH1A1L3MBTL1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-11-20 US claimed
EP-4538261-A1 N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) 2025-04-16 EP claimed
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-11-20 US disclosed
EP-4538261-A1 N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) 2025-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF BDKRB1, BDKRB2, UTS2R ALDH1A1 2190/4885L3MBTL1 2674/4885MEN1 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.